Hépatite chronique B : qui traiter et comment ?

EASL International Consensus Conference on Hepatitis B.13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39S1:S3-25. Lok, 2001, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B, Hepatology, 34, 1225, 10.1053/jhep.2001.29401 Ganem, 2004, Hepatitis B virus infection — natural history and clinical consequences, N Engl J Med, 350, 1118, 10.1056/NEJMra031087 Cadranel, 2000, Practices of liver biopsy in France: results of a prospective nationwide survey For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF), Hepatology, 32, 477, 10.1053/jhep.2000.16602 Nousbaum, 2002, Clinical practice guidelines on the use of liver biopsy, Gastroenterol Clin Biol, 26, 848 Marcellin P, Asselah T, Boyer N. Treatment of Chronic Hepatitis B. Journal of Viral Hepatits. In press. Wai, 2002, HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C, Hepatology, 36, 1425 Janssen, 2005, Peginterferon alfa 2b alone or in combination with lamivudine for chronic Hbe Ag-positive hepatitis B: a randomized trial, Lancet, 365, 123, 10.1016/S0140-6736(05)17701-0 Westland, 2003, Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1, Gastroenterology, 125, 107, 10.1016/S0016-5085(03)00700-5 Thomas, 2003, “Mechanisms of action of interferon and nucleoside analogues”, J Hepatol, 39, S93, 10.1016/S0168-8278(03)00207-1 Asselah, 2003, Traitement de l’hépatite C, Encycl Méd Chir Hépatologie Wong, 1993, Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B A meta-analysis, Ann Intern Med, 119, 312, 10.7326/0003-4819-119-4-199308150-00011 Craxi, 2003, Interferon-alpha for HBeAg-positive chronic hepatitis, B J Hepatol, 39S1, S99, 10.1016/S0168-8278(03)00154-5 Brunetto, 2003, Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon, J Hepatol, 39S1, S164, 10.1016/S0168-8278(03)00329-5 Gervais, 2001, Tolerability of treatments for viral hepatitis, Drug Saf, 24, 375, 10.2165/00002018-200124050-00004 Marcellin, 1995, Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction, J Hepatol, 22, 364, 10.1016/0168-8278(95)80291-6 Boyer, 2000, L’interféron pegylé : nouveau progrès dans le traitement de l’hépatite chronique virale C, Gastroenterol Clin Biol, 24, 767 Cooksley, 2003, Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B, J Viral Hepat, 10, 298, 10.1046/j.1365-2893.2003.00450.x Marcellin, 2004, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056/NEJMoa040431 Koskinas, 2002, Assessment of depression in patients with chronic hepatitis: effect of interferon treatment, Dig Dis, 20, 284, 10.1159/000067682 Lai, 1998, A one year trial of lamivudine for chronic hepatitis B, N Engl J Med, 339, 61, 10.1056/NEJM199807093390201 Dienstag, 1999, Lamivudine as initial treatment for chronic hepatitis B in the United States, N Engl J Med, 341, 1256, 10.1056/NEJM199910213411702 Villeneuve, 2000, Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B, Hepatology, 31, 207, 10.1002/hep.510310130 Leung, 2001, Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy, Hepatology, 33, 1527, 10.1053/jhep.2001.25084 Jonas, 2002, Clinical trial of lamivudine in children with chronic hepatitis B, N Engl J Med, 346, 1706, 10.1056/NEJMoa012452 Dienstag, 2003, Histological outcome during long-term lamivudine therapy, Gastroenterology, 124, 105, 10.1053/gast.2003.50013 Liaw, 2003, Results of lamivudine trials in Asia, J Hepatol, 39, S111, 10.1016/S0168-8278(03)00155-7 Song, 2000, Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea, Hepatology, 32, 803, 10.1053/jhep.2000.16665 Zoulim, 2003, Hepatitis B virus resistance to antivirals: clinical implications and management, J Hepatol, 39, S133, 10.1016/S0168-8278(03)00312-X Honkoop, 2000, Severe acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy, Hepatology, 32, 635, 10.1053/jhep.2000.16333 Tassopoulos, 2001, Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy, Hepatology, 34S, 341A Papatheodoridis, 2002, Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease, Hepatology, 36, 219, 10.1053/jhep.2002.33894 Marcellin, 2003, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B, N Engl J Med, 348, 808, 10.1056/NEJMoa020681 Hadziyannis, 2003, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B, N Engl J Med, 348, 800, 10.1056/NEJMoa021812 Hadziyannis, 2005, Adefovir Dipivoxil demonstrates sustained efficacy in HBeAg chronic hepatitis B patients, J Hepatol Perrillo, 2000, Adefovir Dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants, Hepatology, 32, 129, 10.1053/jhep.2000.8626 Schiff, 2003, Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients, Hepatology, 38, 1419 Peters, 2004, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B, Gastroenterology, 126, 91, 10.1053/j.gastro.2003.10.051 Perrillo, 2004, Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus, Gastroenterology, 126, 81, 10.1053/j.gastro.2003.10.050 Benhamou, 2001, Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study, Lancet, 358, 718, 10.1016/S0140-6736(01)05840-8 Serfaty, 2001, Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study, Hepatology, 34, 573, 10.1053/jhep.2001.26819 Schalm, 2000, Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial, Gut, 46, 562, 10.1136/gut.46.4.562 Barbaro, 2001, Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial, J Hepatol, 35, 406, 10.1016/S0168-8278(01)00145-3 Schiff, 2003, Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders, J Hepatol, 38, 818, 10.1016/S0168-8278(03)00076-X Santantonio, 2002, Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study, J Hepatol, 36, 799, 10.1016/S0168-8278(02)00056-9 Tatulli, 2001, Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B, J Hepatol, 35, 805, 10.1016/S0168-8278(01)00201-X Lau G, Piratvisuth T, Luo KX, Marcellin P, Thongsatawat S, Cookslley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, for the Peginterferon alfa-2a HBeAg-positive Chronic Hepatiitis B Study Group. Peginterferon alfa-2a as monotherapy and in combination with lamivudine versus lamivudine monotherapy in patients with HBeAg-positive chronic hepatitis B.NEJM 2004 (in press). Sung, 2003, A randomised double blinde phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patient with chronic hepatitis B; week 52 analysis, Hepatol, 38, S69A Feld, 2003, New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B, Hepatology, 38, 545, 10.1053/jhep.2003.50389 Van Bömmel, 2004, Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection, Hepatology, 40, 1421, 10.1002/hep.20464 Chang, 2004, Entecavir is superior to lamivudine for the treatment of Hbe Ag(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naïve patients, Hepatology, 40, 193A Shouval, 2004, Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive Hbe Ag(-) chronic hepatitis B: results of phase III trial ETV-027, Hepatology, 40, 728A Shiffman, 2004, A double-blind, placebo-controlled trial of emtricitabine (FTC, emtriva) administered once-daily for treatment of chronic hepatitis B virus (HBV) infection, Hepatology, 40, 172A Lai, 2004, A dose-finding study of once-daily oral telbivudine in HBe Ag-positive patients with chronic hepatitis B virus infection, Hepatology, 40, 719, 10.1002/hep.20374 Marcellin, 2004, A phase II, randomized trial evaluating the safety, pharmacokinetics and antiviral activity of clevudine for 12 weeks in patients with chronic hepatitis B, Hepatology, 40, 1129, 10.1002/hep.20257